Search

Your search keyword '"Quintino S"' showing total 4 results
Start Over Author "Quintino S" Topic anemia, sickle cell
4 results on '"Quintino S"'

1. Safety and efficacy of ketorolac continuous infusion for multimodal analgesia of vaso-occlusive crisis in patients with sickle cell disease.

Author

Pinto VM, Gianesin B, Sardo S, Mazzi F, Baiardi G, Menotti S, Piras F, Quintino S, Robello G, Mattioli F, Finco G, Forni GL, and De Franceschi L

Subjects
Adult, Child, Humans, Ketorolac therapeutic use, Acute Pain drug therapy, Tramadol, Anemia, Sickle Cell complications, Anemia, Sickle Cell drug therapy, Hemoglobinopathies, Analgesia
Abstract

Pain is an hallmark of sickle-cell-related acute clinical manifestations as part of acute vaso-occlusive crisis (VOC). In SCD pain has different origins such as vascular or neuropathic pain, which requires multimodal analgesia. This is based on the administration of drugs with different pharmacological mechanisms of action, maximizing analgesia and minimizing their adverse events and the risk of drug-addition in patients experiencing acute-recurrent pain events as in SCD. Ketorolac is a potent non-narcotic analgesic, being relatively safe and effective during pain-management in children and adults. Up to now, there is a lack of safety information on continuous infusion ketorolac as used to control acute pain in patients with SCD, and the benefits/risks ratio needs to be investigated. Here, we report for the first time the safety profile of ketorolac in the special population of patients with SCD. We confirmed that ketorolac in combination with tramadol, an opioid like molecule, is effective in pain control of adult patients with SCD experiencing acute severe VOCs defined by pain visual analog scale. Our study shows that short term (72 h) continuous infusion of ketorolac plus tramadol is not associated with adverse events such as liver or kidney acute disfunction or abnormalities in coagulation parameters during patients' hospitalization and within 30 days after patients discharge. This is extremely important for patients with SCD, who should have access to multimodal therapy to control recurrent acute pain crisis in order to limit central sensitization a fearsome issue of undertreated recurrent acute pain and of chronic pain., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

2. Manual erythroexchange in sickle cell disease: multicenter validation of a protocol predictive of volume to exchange and hemoglobin values.

Author

Gianesin B, Pinto VM, Casale M, Corti P, Fidone C, Quintino S, Voi V, and Forni GL

Subjects
Adult, Anemia, Sickle Cell epidemiology, Blood Volume Determination methods, Erythrocyte Transfusion methods, Female, Humans, Italy epidemiology, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Reproducibility of Results, Young Adult, Anemia, Sickle Cell blood, Anemia, Sickle Cell therapy, Blood Volume physiology, Blood Volume Determination standards, Erythrocyte Transfusion standards, Hemoglobin, Sickle metabolism
Abstract

Manual erythroexchange (MEEX) was proven to be effective and safe in the management of sickle cell disease (SCD). The goal is to quickly reduce the percentage of hemoglobin S (HbS%). A national survey of the Italian Society for Thalassemia and Hemoglobinopathies (SITE) observed a great variability among MEEX protocols none of which were found to be predictive of the values of HbS% and hemoglobin (Hb) after the exchange. Two equations to estimate the HbS% and Hb values to be obtained after MEEX were developed based on the results of the MEEX procedures in place in the centers participating in the present study. A standard protocol was subsequently defined to evaluate the volumes to exchange to obtain the target values of HbS% and Hb. The protocol was tested in 261 MEEX performed in SCD patients followed in the 5 participating centers that belong to the Italian Hemoglobinopathy Comprehensive Care Network, with the support of the SITE. The results showed a correlation between the estimated and measured values of HbS% and Hb (R p 0.95 and 0.65 respectively, p < 0.001). A negligible bias was found for the prediction of HbS% and a bias of 1 g/dl for Hb. From consecutive MEEX, a rate of increase of HbS% between two exchanges of around 0.4% per day (p < 0.001) was measured. This protocol was shown to be effective and safe, as all patients reached the target value of HbS%. All the MEEX procedures were carried out with single venous access. No adverse events or reactions such as hypotension or electrolyte imbalance were reported nor were any complaints concerning the procedures received from patients.

Published
2020
Full Text
View/download PDF

3. Sickle cell disease: a review for the internist.

Author

Pinto VM, Balocco M, Quintino S, and Forni GL

Subjects
Disease Management, Humans, Internal Medicine methods, Internal Medicine trends, Anemia, Sickle Cell complications, Anemia, Sickle Cell physiopathology, Anemia, Sickle Cell therapy
Abstract

Sickle cell disease (SCD) is the most important hemoglobinopathy worldwide in terms of frequency and social impact, recently recognized as a global public health problem by the World Health Organization. It is a monogenic but multisystem disorder with high morbidity and mortality. Vaso-occlusion, hemolytic anemia and vasculopathy are the hallmarks of SCD pathophysiology. This review focuses both on "time-dependent" acute clinical manifestations of SCD and chronic complications commonly described in adults with SCD. The review covers a broad spectrum of topics concerning current management of SCD targeted at the internists and emergency specialists who are increasingly involved in the care of acute and chronic complications of SCD patients.

Published
2019
Full Text
View/download PDF

4. Manual erythroexchange in sickle cell disease: multicenter validation of a protocol predictive of volume to exchange and hemoglobin values

Author

Valeria Pinto, Vincenzo Voi, Barbara Gianesin, Paola Corti, Maddalena Casale, Sabrina Quintino, Gian Luca Forni, Carmelo Fidone, Gianesin, B., Pinto, V. M., Casale, M., Corti, P., Fidone, C., Quintino, S., Voi, V., and Forni, G. L.

Subjects
Adult, Male, medicine.medical_specialty, Thalassemia, Hemoglobin, Sickle, Reproducibility of Result, Predictive Value of Test, Disease, Anemia, Sickle Cell, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Predictive Value of Tests, Electrolyte imbalance, Internal medicine, medicine, Humans, Prospective Studies, Adverse effect, Volumes exchanged, Protocol (science), HbS%, MEEX, Blood Volume, Blood Volume Determination, business.industry, Sickle cell disease, Hb, Reproducibility of Results, Hematology, General Medicine, Middle Aged, medicine.disease, Prospective Studie, Hemoglobinopathy, Italy, 030220 oncology & carcinogenesis, Standard protocol, Female, Hemoglobin, business, Erythrocyte Transfusion, 030215 immunology, Human
Abstract

Manual erythroexchange (MEEX) was proven to be effective and safe in the management of sickle cell disease (SCD). The goal is to quickly reduce the percentage of hemoglobin S (HbS%). A national survey of the Italian Society for Thalassemia and Hemoglobinopathies (SITE) observed a great variability among MEEX protocols none of which were found to be predictive of the values of HbS% and hemoglobin (Hb) after the exchange. Two equations to estimate the HbS% and Hb values to be obtained after MEEX were developed based on the results of the MEEX procedures in place in the centers participating in the present study. A standard protocol was subsequently defined to evaluate the volumes to exchange to obtain the target values of HbS% and Hb. The protocol was tested in 261 MEEX performed in SCD patients followed in the 5 participating centers that belong to the Italian Hemoglobinopathy Comprehensive Care Network, with the support of the SITE. The results showed a correlation between the estimated and measured values of HbS% and Hb (Rp 0.95 and 0.65 respectively, p < 0.001). A negligible bias was found for the prediction of HbS% and a bias of 1g/dl for Hb. From consecutive MEEX, a rate of increase of HbS% between two exchanges of around 0.4% per day (p < 0.001) was measured. This protocol was shown to be effective and safe, as all patients reached the target value of HbS%. All the MEEX procedures were carried out with single venous access. No adverse events or reactions such as hypotension or electrolyte imbalance were reported nor were any complaints concerning the procedures received from patients.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results